Black Swan Sale

50% Off Elite

Get our most powerful screeners, new charting tools, and the fastest ad-
free experience at our best price ever. This deal may never happen again.

INBX

Inhibrx Biosciences Inc

Nov 28 • 04:00PM ET

84.12

+0.46 0.55 %

Healthcare • Biotechnology • USA • NASD

Peers: BPMC ARVN ONC PTCT EXEL PBYI ADAP KPTI IGMS

| Held by: VTI IWM VXF IWN IBB VTWO FESM EES IWC PRFZ

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-10.24	Insider Own	30.04%	Shs Outstand	14.50M	Perf Week	5.36%
Market Cap	1.22B	Forward P/E	-	EPS next Y	-4.76	Insider Trans	-7.42%	Shs Float	10.17M	Perf Month	9.18%
Enterprise Value	1.18B	PEG	-	EPS next Q	-2.08	Inst Own	58.92%	Short Float	11.17%	Perf Quarter	198.30%
Income	-155.09M	P/S	873.87	EPS this Y	-108.00%	Inst Trans	-2.67%	Short Ratio	3.19	Perf Half Y	524.50%
Sales	1.40M	P/B	33.11	EPS next Y	47.17%	ROA	-77.54%	Short Interest	1.14M	Perf YTD	446.23%
Book/sh	2.54	P/C	7.99	EPS next 5Y	-	ROE	-144.07%	52W High	87.83 -4.23%	Perf Year	466.08%
Cash/sh	10.53	P/FCF	-	EPS past 3/5Y	- -	ROIC	-109.61%	52W Low	10.81 678.53%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-69.79% -	Gross Margin	-86.29%	Volatility	7.15% 8.95%	Perf 5Y	-
Dividend TTM	-	EV/Sales	840.89	EPS Y/Y TTM	-	Oper. Margin	-11002.14%	ATR (14)	6.35	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	4.49	Sales Y/Y TTM	-	Profit Margin	-11077.57%	RSI (14)	68.79	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	4.49	EPS Q/Q	24.83%	SMA20	4.80%	Beta	1.22	Target Price	12.00
Payout	0.00%	Debt/Eq	2.90	Sales Q/Q	-	SMA50	51.40%	Rel Volume	0.35	Prev Close	83.66
Employees	161	LT Debt/Eq	2.84	Earnings	Nov 14 BMO	SMA200	214.71%	Avg Volume	355.80K	Price	84.12
IPO	May 29, 2024	Option/Short	Yes / Yes	EPS/Sales Surpr.	-32.56% -	Trades		Volume	123,246	Change	0.55%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-23-24	Initiated	JMP Securities	Mkt Perform

Nov-14-25 06:00AM	Inhibrx Reports Third Quarter 2025 Financial Results (PR Newswire) +6.04%
Nov-04-25 04:01PM	Inhibrx Announces Participation in Upcoming Scientific Conferences (PR Newswire)
Oct-24-25 07:40AM	Inhibrx Biosciences stock soars on chondrosarcoma Phase II victory (Clinical Trials Arena) +102.01%
Oct-23-25 04:05PM	Inhibrx Biosciences Reports Positive Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and Provides Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts (PR Newswire) -10.03%
Oct-22-25 04:01PM	Inhibrx To Host Webcast Presentation of Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and to Provide Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts (PR Newswire) -15.99%
04:05PM	Loading…
Aug-13-25 04:05PM	Inhibrx Reports Second Quarter 2025 Financial Results (PR Newswire) +7.53%
Jul-28-25 11:11AM	Inhibrx Biosciences Advances HexAgon-HN Study for Head, Neck Cancer (Insider Monkey) +6.46%
Jul-17-25 02:05PM	Ligand Pharmaceuticals Stock Earns 84 RS Rating (Investor's Business Daily)
Jul-15-25 01:08PM	Liquidia Stock Gets Relative Strength Rating Lift (Investor's Business Daily)
Jul-10-25 02:24PM	Arcutis Biotherapeutics Stock Scores RS Rating Upgrade (Investor's Business Daily)
May-14-25 04:05PM	Inhibrx Reports First Quarter 2025 Financial Results (PR Newswire) +10.89%
Apr-01-25 04:05PM	Inhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and President (PR Newswire)
Mar-17-25 04:05PM	Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results (PR Newswire)
Jan-21-25 05:01PM	Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer (PR Newswire) +5.19%
Jan-13-25 04:15PM	Inhibrx Biosciences Announces Loan Agreement with Oxford Finance (PR Newswire) -6.60%
04:24PM	Loading…
Nov-14-24 04:24PM	Inhibrx Biosciences Reports Third Quarter 2024 Financial Results (PR Newswire) -7.25%
Nov-04-24 04:00PM	Inhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and Innovation (PR Newswire)
Sep-13-24 01:55AM	Director Kristiina Vuori Purchases Shares of Inhibrx Biosciences Inc (INBX) (GuruFocus.com) +8.82%
Aug-13-24 06:54PM	Inhibrx Biosciences Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights (PR Newswire)
May-24-24 04:00PM	Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi (PR Newswire)
May-10-24 06:36PM	Inhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-Off (PR Newswire)

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
VIKING GLOBAL INVESTORS LP	10% Owner	Oct 07 '25	Sale	32.25	350,000	11,287,500	67,018	Oct 09 04:41 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Black Swan Sale

50% Off Elite

INBX

Inhibrx Biosciences Inc

Upgrade your FINVIZ experience